Gylden Pharma
  • About Us
    • Leadership
    • Careers
    • Contact Us
  • Our Technology
  • Our Science
    • Pipeline
    • Advantages of Gylden’s Candidates
  • News and Events
    • In the News
    • Press Releases
    • White Papers
    • Data & Congress Presentations
  • Menu Menu
You are here: Home1 / News and Events2 / Press Releases3 / White Papers

White Papers

In these White Papers we describe the challenges of developing effective vaccines for Zika, Influenza (flu), and COVID-19 and explain the benefits of CD8+ priming, Gylden’s set-point vaccines and why we believe our approach addresses many of the issues:

  • Pandemic Vaccine White Paper – Update December 2024
  • COVID-19 White Paper – Update December 2020
  • The Case for T-Cell Vaccines for Elimination, and for Control of Transmission, of COVID-19 – 31 August 2020
  • CD8+ Priming as an Artificial Method for Inducing Herd Immunity into a Population White Paper – 3 April 2020
  • Scientific Rationale for the Use of T cell Priming to Limit the Spread of COVID-19 During Active Pandemic White Paper – 31 March 2020
  • A Case for a Universal Coronavirus Vaccine White Paper – 18 March 2020
  • Flu Vaccine White Paper – August 2018
  • Zika White Paper – August 2018

© Gylden Pharma

Website maintained by Digital Trading

  • Contact Us
LinkedIn x
Scroll to top